Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
14.93
-0.05 (-0.33%)
At close: Aug 13, 2025, 4:00 PM
14.67
-0.27 (-1.77%)
Pre-market: Aug 14, 2025, 9:13 AM EDT
Oscar Health Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Oscar Health stock ranges from a low of $10 to a high of $18. The average analyst price target of $12.79 forecasts a -14.33% decrease in the stock price over the next year.
Price Target: $12.79 (-14.33%)
Analyst Consensus: Sell
Analyst Ratings
The average analyst rating for Oscar Health stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 3 | 3 | 3 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 2 | 1 | 1 |
Sell | 2 | 2 | 2 | 2 | 4 | 4 |
Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
Total | 8 | 8 | 8 | 5 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Baird | Baird | Buy → Hold Downgrades $28 → $14 | Buy → Hold | Downgrades | $28 → $14 | -6.23% | Jul 25, 2025 |
Barclays | Barclays | Sell Maintains $17 → $11 | Sell | Maintains | $17 → $11 | -26.32% | Jul 23, 2025 |
UBS | UBS | Hold → Strong Sell Downgrades $15 → $11 | Hold → Strong Sell | Downgrades | $15 → $11 | -26.32% | Jul 15, 2025 |
Wells Fargo | Wells Fargo | Hold → Sell Downgrades $16 → $10 | Hold → Sell | Downgrades | $16 → $10 | -33.02% | Jul 11, 2025 |
Barclays | Barclays | Sell Initiates $17 | Sell | Initiates | $17 | +13.86% | Jul 2, 2025 |
Financial Forecast
Revenue This Year
12.03B
from 9.18B
Increased by 31.12%
Revenue Next Year
11.31B
from 12.03B
Decreased by -6.01%
EPS This Year
0.70
from 0.10
Increased by 603.80%
EPS Next Year
0.90
from 0.70
Increased by 28.36%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | 12.7B | 13.3B | 14.9B |
Avg | 12.0B | 11.3B | 13.1B |
Low | 11.0B | 10.0B | 9.6B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 38.6% | 10.7% | 32.1% |
Avg | 31.1% | -6.0% | 15.7% |
Low | 20.1% | -16.9% | -14.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.92 | 1.97 | 2.36 |
Avg | 0.70 | 0.90 | 1.67 |
Low | 0.58 | 0.09 | 0.54 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 824.0% | 180.5% | 161.5% |
Avg | 603.8% | 28.4% | 85.2% |
Low | 478.2% | -87.5% | -40.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.